SS-31 Peptide, also known as Elamipretide, is a synthetic tetrapeptide designed to selectively target the inner mitochondrial membrane. With sequence D-Arg-Dmt-Lys-Phe-NH2, it demonstrates unique affinity for cardiolipin, a crucial phospholipid for mitochondrial function. Its structure allows cell membrane penetration, supporting mitochondrial health.
Context
Within cellular machinery, SS-31 operates specifically at the mitochondria, the cell’s primary energy generators. It localizes to the inner mitochondrial membrane, interacting with cardiolipin. This interaction is pivotal for maintaining electron transport chain integrity, fundamental to cellular respiration and ATP production.
Significance
Clinically, SS-31 Peptide holds promise for conditions involving mitochondrial dysfunction and oxidative stress, underlying numerous chronic diseases and aging. Supporting mitochondrial health can improve cellular bioenergetics, potentially mitigating organ damage and enhancing patient well-being in scenarios like ischemia-reperfusion injury.
Mechanism
SS-31’s action stems from its ability to selectively scavenge reactive oxygen species (ROS) within mitochondria, particularly from oxidative phosphorylation. By stabilizing cardiolipin, it preserves optimal structure and function of respiratory supercomplexes. This reduces oxidative damage, improves electron flow, enhancing ATP synthesis and restoring mitochondrial efficiency.
Application
SS-31 Peptide is primarily an investigational compound undergoing clinical evaluation where mitochondrial integrity is compromised. Research explores its potential in chronic kidney disease, heart failure, and ophthalmic disorders. Administration routes typically include intravenous or subcutaneous delivery, depending on clinical context.
Metric
Assessing SS-31’s impact involves monitoring key biomarkers related to mitochondrial function and oxidative stress. Measurements may include cellular ATP levels, oxygen consumption rates, and markers of lipid peroxidation. Clinically, improvements in organ-specific function tests, like estimated glomerular filtration rate or ejection fraction, indicate therapeutic effect.
Risk
As an investigational therapeutic agent, SS-31 Peptide carries potential considerations. While generally well-tolerated, possible adverse effects could include injection site reactions or transient systemic responses. Long-term safety data are still being accumulated, emphasizing rigorous clinical oversight and patient monitoring during its investigation.
We use cookies to personalize content and marketing, and to analyze our traffic. This helps us maintain the quality of our free resources. manage your preferences below.
Detailed Cookie Preferences
This helps support our free resources through personalized marketing efforts and promotions.
Analytics cookies help us understand how visitors interact with our website, improving user experience and website performance.
Personalization cookies enable us to customize the content and features of our site based on your interactions, offering a more tailored experience.